{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:41:41Z","timestamp":1767339701865,"version":"build-2065373602"},"reference-count":69,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,12,11]],"date-time":"2022-12-11T00:00:00Z","timestamp":1670716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Early in the COVID-19 pandemic, it was recognized that infection with SARS-CoV-2 is associated with increased morbidity and mortality in patients with cancer; therefore, preventive vaccination in cancer survivors is expected to be particularly impactful. Heterogeneity in how a neoplastic disease diagnosis and treatment interferes with humoral and cellular immunity, however, poses a number of challenges in vaccination strategies. Herein, the available literature on the effectiveness of COVID-19 vaccines among patients with cancer is critically appraised under the lens of anti-neoplastic treatment optimization. The objective of this review is to highlight areas of uncertainty, where more research could inform future SARS-CoV-2 immunization programs and maximize benefits in the high-risk cancer survivor population, and also minimize cancer treatment deviations from standard practices.<\/jats:p>","DOI":"10.3390\/vaccines10122117","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T03:02:37Z","timestamp":1670814157000},"page":"2117","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Areas of Uncertainty in SARS-CoV-2 Vaccination for Cancer Patients"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3950-3305","authenticated-orcid":false,"given":"Anastasios","family":"Dimou","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ccell.2020.07.006","article-title":"Cancer Patients and Risk of Mortality for COVID-19","volume":"38","author":"Curigliano","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1001\/jamaoncol.2021.4083","article-title":"COVID-19 and Cancer: A Review of the Registry-Based Pandemic Response","volume":"7","author":"Desai","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejca.2020.08.011","article-title":"Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies","volume":"139","author":"Saini","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"587269","DOI":"10.3389\/fcimb.2020.587269","article-title":"SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development","volume":"10","author":"Wang","year":"2020","journal-title":"Front. Cell Infect. Microbiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s12276-021-00592-0","article-title":"Type I and III interferon responses in SARS-CoV-2 infection","volume":"53","author":"Kim","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.amjms.2020.09.017","article-title":"The Association of \u201cLoss of Smell\u201d to COVID-19: A Systematic Review and Meta-Analysis","volume":"361","author":"Aziz","year":"2021","journal-title":"Am. J. Med. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Grant, M.C., Geoghegan, L., Arbyn, M., Mohammed, Z., McGuinness, L., Clarke, E.L., and Wade, R.G. (2020). The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries. PLoS ONE, 15.","DOI":"10.2139\/ssrn.3582819"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1016\/S2589-7500(21)00115-1","article-title":"Anosmia, ageusia, and other COVID-19-like symptoms in association with a positive SARS-CoV-2 test, across six national digital surveillance platforms: An observational study","volume":"3","author":"Sudre","year":"2021","journal-title":"Lancet Digit Health"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1056\/NEJMcp2009575","article-title":"Severe COVID-19","volume":"383","author":"Berlin","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ajem.2020.09.072","article-title":"SARS-CoV-2 infection and its association with thrombosis and ischemic stroke: A review","volume":"40","author":"Snell","year":"2021","journal-title":"Am. J. Emerg. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2000895","DOI":"10.2807\/1560-7917.ES.2020.25.48.2000895","article-title":"Clinical characteristics and risk factors associated with severe COVID-19: Prospective analysis of 1045 hospitalised cases in North-Eastern France, March 2020","volume":"25","author":"Kaeuffer","year":"2020","journal-title":"Eurosurveillance"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e2111417","DOI":"10.1001\/jamanetworkopen.2021.11417","article-title":"Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19: A Systematic Review","volume":"4","author":"Nasserie","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and Efficacy of NVX-CoV2373 COVID-19 Vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against COVID-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1146\/annurev-med-042420-113212","article-title":"Whole Inactivated Virus and Protein-Based COVID-19 Vaccines","volume":"73","author":"Hotez","year":"2022","journal-title":"Annu. Rev. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/S1473-3099(22)00502-3","article-title":"Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): Interim analysis of a randomised, controlled, phase 3, immunobridging trial","volume":"22","author":"Lazarus","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/jamaoncol.2021.2675","article-title":"Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer","volume":"7","author":"Waldhorn","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1001\/jamaoncol.2021.5437","article-title":"Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations","volume":"8","author":"Mair","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1038\/s41375-021-01270-w","article-title":"COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia","volume":"35","author":"Roeker","year":"2021","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ccell.2021.06.014","article-title":"Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma","volume":"39","author":"Gleason","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41586-022-04474-x","article-title":"Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity","volume":"603","author":"Meng","year":"2022","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.1158\/0008-5472.CAN-21-3554","article-title":"Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer","volume":"81","author":"Figueiredo","year":"2021","journal-title":"Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.mayocpiqo.2021.12.004","article-title":"Humoral Responses After SARS-CoV-2 mRNA Vaccination and Breakthrough Infection in Cancer Patients","volume":"6","author":"Chumsri","year":"2022","journal-title":"Mayo Clin. Proc. Innov. Qual. Outcomes"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jamaoncol.2022.0001","article-title":"Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida","volume":"8","author":"Giuliano","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/2643-3230.BCD-21-0222","article-title":"CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity","volume":"3","author":"Shree","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/ni.1877","article-title":"PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells","volume":"11","author":"Szumilas","year":"2010","journal-title":"Nat. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/s41590-019-0441-y","article-title":"PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1(+)CD38(hi) cells and anti-PD-1 resistance","volume":"20","author":"Verma","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Chen, Y., Tong, P., Whiteman, N., Moghaddam, A.S., Zarghami, M., Zuiani, A., Habibi, S., Gautam, A., Keerti, F., and Bi, C. (2022). Immune recall improves antibody durability and breadth to SARS-CoV-2 variants. Sci. Immunol., eabp8328.","DOI":"10.1126\/sciimmunol.abp8328"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.cell.2022.04.009","article-title":"Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine","volume":"185","author":"Goel","year":"2022","journal-title":"Cell"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0140-6736(22)00462-7","article-title":"Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: A cohort study","volume":"399","author":"Nyberg","year":"2022","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-022-04465-y","article-title":"Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron","volume":"603","author":"Liu","year":"2022","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"100204","DOI":"10.1016\/j.xcrm.2021.100204","article-title":"Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases","volume":"2","author":"Tarke","year":"2021","journal-title":"Cell Rep. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.1016\/S2666-5247(22)00036-2","article-title":"SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: A longitudinal cohort study","volume":"3","author":"Guo","year":"2022","journal-title":"Lancet Microbe"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood.2020008824","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients","volume":"136","author":"Vijenthira","year":"2020","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/acr2.11386","article-title":"Coronavirus Disease 2019 Outcomes Among Recipients of Anti-CD20 Monoclonal Antibodies for Immune-Mediated Diseases: A Comparative Cohort Study","volume":"4","author":"Patel","year":"2022","journal-title":"ACR Open Rheumatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"103382","DOI":"10.1016\/j.msard.2021.103382","article-title":"Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab","volume":"57","author":"Katz","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/s41591-021-01507-2","article-title":"Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy","volume":"27","author":"Apostolidis","year":"2021","journal-title":"Nat. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/s43018-021-00275-9","article-title":"Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: The CAPTURE study","volume":"2","author":"Fendler","year":"2021","journal-title":"Nat Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.ccell.2021.07.016","article-title":"Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer","volume":"39","author":"Ehmsen","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1128\/CMR.00034-13","article-title":"Gamma interferon release assays for detection of Mycobacterium tuberculosis infection","volume":"27","author":"Pai","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e13220","DOI":"10.1111\/petr.13220","article-title":"Quantiferon-Cytomegalovirus assay: A potentially useful tool in the evaluation of CMV-specific CD8+ T-cell reconstitution in pediatric hematopoietic stem cell transplant patients","volume":"22","author":"Paouri","year":"2018","journal-title":"Pediatr. Trans."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/jmv.24031","article-title":"Varicella-zoster virus-specific, cell-mediated immunity with interferon-gamma release assay after vaccination of college students with no or intermediate IgG antibody response","volume":"87","author":"Terada","year":"2015","journal-title":"J. Med. Virol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"105098","DOI":"10.1016\/j.jcv.2022.105098","article-title":"Accuracy and real life performance of a novel interferon-gamma release assay for the detection of SARS-CoV2 specific T cell response","volume":"148","author":"Huzly","year":"2022","journal-title":"J. Clin. Virol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e0219921","DOI":"10.1128\/jcm.02199-21","article-title":"A Pilot Study for the Evaluation of an Interferon Gamma Release Assay (IGRA) To Measure T-Cell Immune Responses after SARS-CoV-2 Infection or Vaccination in a Unique Cloistered Cohort","volume":"60","author":"Barreiro","year":"2022","journal-title":"J. Clin. Microbiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijid.2021.06.054","article-title":"Interferon-gamma release assay testing to assess COVID-19 vaccination response in a SARS-CoV-2 seronegative patient on rituximab: A case report","volume":"110","author":"Ferguson","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jtcvs.2021.11.092","article-title":"Safety of lung cancer surgery during COVID-19 in a pandemic epicenter","volume":"164","author":"Lutton","year":"2022","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"735.e1","DOI":"10.1016\/j.ajog.2022.06.052","article-title":"Outcomes of gynecologic cancer surgery during the COVID-19 pandemic: An international, multicenter, prospective CovidSurg-Gynecologic Oncology Cancer study","volume":"227","author":"Fotopoulou","year":"2022","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.hpb.2022.03.002","article-title":"Outcomes of patients undergoing elective liver and pancreas cancer surgery during the SARS-CoV-2 pandemic: An international, multicentre, prospective cohort study","volume":"24","author":"McKay","year":"2022","journal-title":"HPB"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bja.2021.05.018","article-title":"Mortality after surgery with SARS-CoV-2 infection in England: A population-wide epidemiological study","volume":"127","author":"Abbott","year":"2021","journal-title":"Br. J. Anaesth."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.21873\/invivo.12383","article-title":"The Impact of COVID-19 Infection on the Postoperative Outcomes in Pancreatic Cancer Patients","volume":"35","author":"Bacalbasa","year":"2021","journal-title":"In Vivo"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ijsu.2020.10.019","article-title":"A cohort study of 30 day mortality after NON-EMERGENCY surgery in a COVID-19 cold site","volume":"84","author":"Kasivisvanathan","year":"2020","journal-title":"Int. J. Surg."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ygyno.2022.02.013","article-title":"Impact of the COVID-19-pandemic on patients with gynecological malignancies undergoing surgery: A Dutch population-based study using data from the \u2018Dutch Gynecological Oncology Audit\u2019","volume":"165","author":"Algera","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"754838","DOI":"10.3389\/fonc.2021.754838","article-title":"Management and Outcomes of Patients With Radiotherapy Interruption During the COVID-19 Pandemic","volume":"11","author":"Ying","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1470-2045(20)30743-9","article-title":"The impact of the COVID-19 pandemic on radiotherapy services in England, UK: A population-based study","volume":"22","author":"Spencer","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.radonc.2020.04.019","article-title":"Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement","volume":"151","author":"Thomson","year":"2020","journal-title":"Radiother Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ijrobp.2020.05.012","article-title":"Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement","volume":"107","author":"Guckenberger","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejca.2020.09.035","article-title":"Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)","volume":"141","author":"Lievre","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.annonc.2021.02.024","article-title":"Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: A report from the COVID-19 and Cancer Consortium","volume":"32","author":"Grivas","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"van Marcke, C., Honore, N., van der Elst, A., Beyaert, S., Derouane, F., Dumont, C., Nana, F.A., Baurain, J.F., Borbath, I., and Collard, P. (2021). Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: A cohort study. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08349-8"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2020.04.004","article-title":"COVID-19 in lung cancer patients receiving ALK\/ROS1 inhibitors","volume":"132","author":"Leonetti","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1200\/JCO.19.00354","article-title":"Influenza Vaccine Effectiveness Among Patients With Cancer: A Population-Based Study Using Health Administrative and Laboratory Testing Data From Ontario, Canada","volume":"37","author":"Blanchette","year":"2019","journal-title":"J. Clin. Oncol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/12\/2117\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:38:00Z","timestamp":1760146680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/12\/2117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,11]]},"references-count":69,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["vaccines10122117"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10122117","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2022,12,11]]}}}